Pneumococcal Vaccination Guidelines for Immunocompromised Adults

Risk Assessment

Patients with a history of cancer, including those with renal cancer who have undergone nephrectomy, are considered immunocompromised and at higher risk for pneumococcal disease 2
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices recommends pneumococcal vaccination for adults aged 19-64 years with specific risk factors, including immunocompromising conditions 1
Cancer patients, particularly those who have undergone surgical interventions like nephrectomy, have altered immune responses that increase susceptibility to infections 3

For adults aged 19-64 years with immunocompromising conditions (including cancer), the CDC recommends either a single dose of PCV20 alone, or PCV15 followed by PPSV23 at least 1 year later 2, 1
The 23-valent pneumococcal vaccine contains capsular types that represent 85-90% of serotypes causing invasive pneumococcal infections in the United States 4, 5
The six serotypes most frequently causing invasive drug-resistant pneumococcal infection are included in the vaccine 4

While patients with cancer may have diminished immune responses to pneumococcal vaccination compared to healthy individuals, vaccination still provides significant protection 4, 6
Antibody response to pneumococcal vaccination develops within 2-3 weeks in ≥80% of healthy young adults, though responses may vary in immunocompromised patients 5
Levels of antibodies to most pneumococcal vaccine antigens remain elevated for at least 5 years in healthy adults 5

Pneumococcal vaccination significantly reduces the risk of invasive pneumococcal disease and pneumonia in high-risk populations 2

The pneumococcal vaccine can be administered concurrently with other vaccines, including the influenza vaccine, without increased side effects 1
Vaccination should ideally be administered at least 2 weeks before initiation of immunosuppressive therapy if the patient is scheduled to receive such treatment 1
No need to delay vaccination if the patient is clinically stable post-nephrectomy 1

Failing to recognize cancer as an indication for pneumococcal vaccination before age 65 1
Delaying vaccination unnecessarily, as timely immunization provides optimal protection against pneumococcal disease 2